Drug Trial Radar · NCT04919642
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Last checked: Nov 19, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Dec 7, 2021
Primary completion
Feb 28, 2024
Study completion Feb 28, 2024
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.
Conditions
- Cholangiocarcinoma
- FGFR2 Fusion
- FGFR2 Gene Mutation
- FGFR1 Alteration
- FGFR3 Alteration
Interventions
TT-00420Drug
TT-00420 tablet, administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in patients with FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor (Cohort A1)Time frame: Through study completion, an average of 9 months.
- ORR in patients with FGFR2 fusions who have responded (CR or PR) on at least one previous treatment with an FGFR inhibitor and discontinued due to progressive disease (Cohort A2)Time frame: Through study completion, an average of 9 months.
- ORR in patients with FGFR alterations other than FGFR2 fusions (Cohort B)Time frame: Through study completion, an average of 9 months.
- ORR in patients without FGFR alterations (wild-type FGFR mutation status) (Cohort C)Time frame: Through study completion, an average of 9 months.
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Providence Cancer Center
Anchorage, Alaska
City of Hope
Duarte, California
University of California, Los Angeles, School of Medicine
Santa Monica, California
USO Oncology Network- Rocky Mountain Cancer Centers
Denver, Colorado
Mount Sinai Medical Center
Miami Beach, Florida
University of Chicago Medical Center - Duchossis Center for Advanced Medicine
Chicago, Illinois
University of Maryland - Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Henry Ford Health Center
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada
Summit Medical Group - Florham Park Campus
Florham Park, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Ruttenberg Treatment Center - Mount Sinai
New York, New York
USOR Oncology Network- New York Oncology
New York, New York
Stony Brook University - Long Island Cancer Center
Stony Brook, New York
University of Cincinnati Cancer Institute
Cincinnati, Ohio
University Hospitals Seidman Cancer Center
Cleveland, Ohio
USO Oncology Network-Northwest Cancer Specialists, P.C.
Portland, Oregon
Medical College of South Carolina
Charleston, South Carolina
The University of Tennessee Medical Center
Knoxville, Tennessee
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee
Methodist Dallas Medical Center
Dallas, Texas
Parkland Health & Hospital System
Dallas, Texas
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
Houston Methodist Hospital - Outpatient Center
Houston, Texas
UT MD Anderson Cancer Center
Houston, Texas
USO Oncology Network-Texas Oncology
Tyler, Texas
USO Oncology Network-Virginia Oncology Associates - Brock Cancer Center - Norfolk
Norfolk, Virginia
USO Oncology Network-Oncology and Hematology Associates of Southwest Virginia, Inc.
Roanoke, Virginia
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.